H-Aggregated IR-1061 for NIR-II Cancer Therapy

The study by Yu et al., published in Nano Convergence, addresses a persistent challenge in theranostic nanomedicine: how to combine high-quality near-infrared fluorescence imaging with efficient photothermal therapy (PTT) in one organic fluorophore system. The reference study uses IR-1061 in a targeted liposomal formulation to coordinate tumor visualization, light-triggered heating, and carboplatin delivery.

Its central contribution is not simply the selection of an NIR-II dye. Instead, the work treats the aggregation state of IR-1061 as a controllable functional parameter. The fluorophore is maintained in an H-aggregated state within the liposome and then transferred to the tumor cell membrane after peptide-mediated membrane fusion. This state-dependent design aims to preserve NIR-II fluorescence for imaging while enhancing photothermal conversion in the tumor microenvironment.

Study Background and Research Question

PTT is attractive for cancer treatment because externally applied NIR light can generate local heat with limited mechanical invasion. In practice, however, effective PTT requires accurate tumor localization, sufficient accumulation of the photothermal agent, and controlled thermal exposure. Fluorescence imaging can help address the first two issues, but conventional visible-light imaging is limited by tissue scattering, absorption, and autofluorescence.

NIR-II fluorescence imaging, generally described in the 1000–1700 nm range, can provide improved tissue penetration and spatial resolution relative to shorter-wavelength optical approaches because biological tissues scatter and absorb less light in this region, as described in the reference paper. This makes IR-1061 relevant as a near infrared fluorescent dye for biomedical research and as a fluorescent dye for in vivo imaging when it is incorporated into a suitable delivery system.

The researchers focused on a photophysical trade-off. Organic small-molecule fluorophores often favor radiative emission, whereas strong photothermal activity requires efficient nonradiative energy dissipation. Prior strategies based on structural distortion or twisted intramolecular charge transfer can introduce instability or reduce fluorescence after the dye leaves its carrier. Yu et al. therefore asked whether controlled aggregation could produce a more stable division of imaging and heating functions.

Key Innovation from the Reference Study

The formulation, named RRIALP-C4, consists of anionic liposomes loaded with IR-1061 and the chemotherapeutic drug carboplatin. The liposome surface is functionalized with the cationic nona-arginine-containing peptide RR9, reported as RGDRRRRRRRRC in the study. The peptide provides two related functions: recognition of αvβ3-overexpressed tumor cells and enhanced interaction with cell membranes.

The mechanistic innovation is the proposed transfer of the H-aggregated fluorophore from the phospholipid bilayer to the tumor cell membrane. H aggregation involves face-to-face molecular stacking and can produce optical and energy-relaxation behavior distinct from the freely dispersed dye. In RRIALP-C4, the formulation is designed so that IR-1061 remains associated with the liposomal membrane during transport, while RR9-assisted fusion places the fluorophore in the tumor cell membrane.

This creates a two-state, dual-channel concept. The system supports NIR-II fluorescence imaging for tumor and vascular visualization, while the membrane-associated H-aggregated state supports NIR-I photothermal heating. Carboplatin adds a chemical treatment component, and local heat is also used to promote temperature-sensitive drug release. The importance of this design is that the carrier is not treated as an inert container; its lipid environment and subsequent membrane transfer are part of the therapeutic mechanism.

Methods and Experimental Design Insights

The experimental workflow links molecular modeling, nanosystem construction, optical characterization, cellular targeting, and animal evaluation. Molecular dynamics simulations were used to examine how IR-1061 interacts with the phospholipid bilayer. This modeling step provided a rationale for why the fluorophore could adopt an H-aggregated arrangement in the liposome rather than remaining in a free molecular state.

The formulation was then assembled as an anionic liposome containing IR-1061 and carboplatin, followed by RR9 modification. The study evaluated whether this architecture retained the intended imaging signal, produced photothermal activity, and supported membrane fusion or transfer to targeted tumor cells. In vivo experiments assessed tumor imaging, systemic blood-vessel visualization, photothermal treatment, drug release, and combined therapeutic efficacy.

Protocol Parameters

• Fluorophore environment: Treat the lipid bilayer as a functional component of the design; characterize IR-1061 in its free and H-aggregated states rather than assuming that solution-phase behavior predicts liposomal performance.
• Carrier composition: Use an anionic liposome containing both IR-1061 and carboplatin when reproducing the reported RRIALP-C4 concept. Confirm loading, colloidal stability, and the preservation of the intended aggregate state before biological testing.
• Surface targeting: Include RR9 only when the experimental objective requires αvβ3-associated tumor targeting and membrane interaction. Peptide density and coupling chemistry should be independently optimized because they can influence circulation, uptake, and fusion.
• Imaging workflow: Use NIR-II fluorescence to locate tumors and vessels before irradiation. The reported NIR-II window spans 1000–1700 nm, but detector sensitivity, filters, tissue depth, and exposure settings should be calibrated for the specific instrument.
• Photothermal workflow: Measure temperature at the tumor region during NIR irradiation and include an irradiation-only control. Heating conditions should be transferred from the paper cautiously because laser geometry, tissue depth, anesthesia, and thermometry can change the effective dose.
• Combination treatment: Coordinate imaging, irradiation, and carboplatin release measurements in the same formulation. A useful control structure separates free or non-targeted dye, liposomal dye without peptide, chemotherapy-only treatment, and combined treatment whenever material availability permits.

These parameters distinguish reported design principles from universal operating conditions. The paper supports the rationale for coupling H aggregation, membrane transfer, and thermochemotherapy, but it does not eliminate the need for formulation-specific characterization and animal-model validation.

Core Findings and Why They Matter

First, the study provides evidence that IR-1061 can be used in a carrier-dependent optical design rather than being evaluated only as a freely dispersed fluorophore. The liposomal environment promotes H aggregation, and the RR9 coating is intended to move that state to the tumor cell membrane. This is significant because it addresses the common problem of losing photothermal performance when a dye changes environment after administration.

Second, RRIALP-C4 enabled visualization of tumor tissues and systemic blood vessels with a high signal-to-background ratio according to the reference study. For a fluorescent dye for optical imaging, this is an important practical endpoint: imaging quality is not only a measure of brightness but also of contrast against surrounding tissue. NIR-II detection can be particularly useful when deep-tissue background limits shorter-wavelength measurements.

Third, the formulation supported combined PTT and chemotherapy. Photothermal heating was used to damage tumor tissue and to promote temperature-sensitive carboplatin release, creating a thermochemotherapy strategy rather than two independent treatments administered in parallel. The reported results indicate that membrane-associated H aggregation strengthened the PTT component and that the combined treatment produced more effective tumor suppression than the individual functions considered separately.

Fourth, the work suggests a broader formulation principle for a fluorescent dye for in vivo imaging: the biological destination of the dye may be as important as its initial nanoparticle location. Liposome-to-membrane transfer can influence aggregation, fluorescence, heating, cellular uptake, and drug release simultaneously. This gives researchers a concrete way to connect molecular-scale organization with whole-animal imaging and therapy outcomes.

Comparison with Existing Internal Articles

The internal article IR-1061 for Deep Tissue Imaging: Protocols, Pitfalls, and Reliability is complementary to this paper because it focuses on workflow reliability and interpretation for IR-1061-based imaging. The Yu et al. study adds a more specialized mechanistic layer: its emphasis is not only deep-tissue signal but also how lipid organization and tumor-cell membrane transfer alter the dye’s therapeutic role.

A second useful comparison is Biodegradable IR-1061 Polymer Nanoparticles for Deep NIR-II Imaging. That resource discusses polymer micelle encapsulation, whereas the reference study uses an anionic liposome with peptide targeting and carboplatin co-loading. The comparison highlights that IR-1061 performance is formulation-dependent. Polymer micelles may prioritize stability and imaging, while RRIALP-C4 is engineered for targeting, membrane transfer, photothermal treatment, and drug release. Results from one carrier class should therefore not be generalized to another without direct testing.

Limitations and Transferability

The most important limitation is that the reported function depends on a complex sequence of events: liposome formation, H aggregation, blood transport, αvβ3-associated targeting, membrane fusion, photothermal heating, and temperature-sensitive drug release. Variability in lipid composition, peptide presentation, particle size, aggregation state, or carboplatin loading could change the outcome. Each batch therefore requires physicochemical and optical quality control.

Animal evidence also cannot be treated as a direct prediction of clinical performance. Tumor vascularity, αvβ3 expression, immune clearance, tissue penetration, and drug sensitivity vary among models and patients. NIR-II imaging requires appropriate detectors and optical filters, while photothermal treatment requires controlled dosimetry and reliable temperature measurement. These instrumentation and biological factors limit direct transfer to laboratories with different equipment or disease models.

There is also a distinction between IR-1061 as a chemical reagent and RRIALP-C4 as a finished therapeutic nanosystem. The study’s findings apply to the formulated, targeted liposome and should not be interpreted as evidence that unformulated IR-1061 alone will reproduce the same membrane transfer or thermochemotherapy behavior. Researchers should independently assess solubility, aggregation, encapsulation, stability, cytotoxicity, and biodistribution for their own formulation.

Nevertheless, the paper offers a useful design hypothesis: controlling the spatial organization of an organic NIR-II fluorophore can help reconcile imaging and photothermal functions. Its strongest transferable lesson is methodological—combine molecular-level modeling with formulation analysis and in vivo validation instead of optimizing fluorescence, heating, or targeting in isolation.

Research Support Resources

Researchers planning related imaging or formulation experiments can use IR-1061 (SKU C8242) to support similar workflows. The product information identifies it as a near infrared fluorescent dye with the formula C44H34BClF4S2 and molecular weight 749.13, and reports solubility in DMSO at concentrations of at least 25.65 mg/mL while describing it as insoluble in ethanol and water. Freshly prepared DMSO solutions are preferable, and the solid should be tightly sealed, kept desiccated, and stored at −20 °C according to the product information. These handling details are starting points for reagent preparation; they do not replace validation of liposomal loading, H aggregation, or biological performance in the specific RR9–carboplatin system.